Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbingdon Healt. Regulatory News (ABDX)

Share Price Information for Abingdon Healt. (ABDX)

Share Price is delayed by 15 minutes
Get Live Data
11.25    0.00 (0.00%)
Bid:
11.00
Ask:
11.50
Spread: 0.50 (4.545%)
Market Cap: £28.25m
ABDX Live PriceLast checked at - London Stock Exchange

Intraday Abingdon Healt. Share Chart

Presentation at Mello2026

29 May 2026 07:00

RNS Number : 1355G
Abingdon Health PLC
29 May 2026
 

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

Presentation at Mello2026

 

York, UK and Madison, WI, USA, 29 May 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that Executive Chairman, Chris Hand and CFO, Tom Hayes, will be presenting at the Mello2026 investor event on Tuesday 2 June 2026. The event is taking place at The Clayton Hotel & Conference Centre, Chiswick High Road, London, W4 5RY. 

 

Abingdon Health will be presenting twice during the event at 11:35 and 16:10. There will also be opportunity to interact with the management team at the Company's exhibitor stand. For further information and tickets for the Mello2026 conference, please visit the event website at www.melloevents.com/mello2026 (use code SHM2026 for 25% off ticket price).

 

Any shareholders wishing to keep up to date with Abingdon Health news, please email abingdon@walbrookpr.com

 

Enquiries:

 

Abingdon Health plc

www.abingdonhealth.com/investors/

Chris Hand, Executive Chairman

Via Walbrook PR

Tom Hayes, CFO

Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser)

Tel: +44 (0)20 7220 0500

Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance)

Nigel Birks (Life Science Specialist Sales)

Walbrook PR (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com

Paul McManus / Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Abingdon Health

 

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.

 

The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory strategy support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring. The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.

 

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

 

Abingdon Health's brochures outlines the comprehensive support the Group can now provide to its international customers. For more information visit: www.abingdonhealth.com.

 

LEI - 213800XFI4WV3FBILO20

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFFAESITFIR
Date   Source Headline
24th Aug 20214:35 pmRNSPrice Monitoring Extension
24th Aug 202111:05 amRNSSecond Price Monitoring Extn
24th Aug 202111:00 amRNSPrice Monitoring Extension
23rd Aug 20214:40 pmRNSSecond Price Monitoring Extn
23rd Aug 20214:35 pmRNSPrice Monitoring Extension
23rd Aug 20212:05 pmRNSSecond Price Monitoring Extn
23rd Aug 20212:00 pmRNSPrice Monitoring Extension
23rd Aug 20217:00 amRNSLaunch of BioSURE COVID-19 IgG Antibody Self Test
12th Aug 20212:00 pmRNSPrice Monitoring Extension
12th Aug 20217:00 amRNSTrading update
9th Aug 202111:15 amRNSDisclosure of Detailed Grounds for Resistance
27th Jul 20217:00 amRNSPublication of an article regarding AbC-19
23rd Jul 20217:00 amRNSExclusive Manufacturing Agreement with BioSure
9th Jul 20217:00 amRNSPeer reviewed study involving AbC 19
5th Jul 20217:00 amRNSManufacturing Agreement with Bioporto A/S
11th Jun 20214:40 pmRNSSecond Price Monitoring Extn
11th Jun 20214:35 pmRNSPrice Monitoring Extension
7th Jun 20214:41 pmRNSSecond Price Monitoring Extn
7th Jun 20214:36 pmRNSPrice Monitoring Extension
27th Apr 20219:05 amRNSSecond Price Monitoring Extn
27th Apr 20219:00 amRNSPrice Monitoring Extension
27th Apr 20217:00 amRNSTrading Update
23rd Apr 20213:02 pmRNSGrant of Options under SAYE Scheme
6th Apr 20211:34 pmRNSDirector Dealing
10th Mar 20214:41 pmRNSSecond Price Monitoring Extn
10th Mar 20214:35 pmRNSPrice Monitoring Extension
10th Mar 20212:06 pmRNSSecond Price Monitoring Extn
10th Mar 20212:00 pmRNSPrice Monitoring Extension
10th Mar 202111:06 amRNSSecond Price Monitoring Extn
10th Mar 202111:00 amRNSPrice Monitoring Extension
9th Mar 20217:00 amRNSInterim Results
24th Feb 20217:00 amRNSData on AbC-19 as CDx for Pfizer-BioNTech Vaccine
23rd Feb 20217:00 amRNSNotice of Interim Results
16th Feb 20217:00 amRNSAbingdon Health Notes Announcement by UK-RTC
9th Feb 20217:00 amRNSCollaboration with Abcam
8th Feb 20217:00 amRNSStatement re Media Article
27th Jan 20216:13 pmRNSMedia Clarification
26th Jan 20217:01 amRNSTrading Update
26th Jan 20217:00 amRNSAppointment of Chief Financial Officer
29th Dec 20207:00 amRNSAbC-19TM Rapid Test Update
15th Dec 20207:00 amRNSADMISSION TO TRADING ON AIM & FIRST DAY DEALINGS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.